The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10611 malaria professionals are enjoying the free benefits of MalariaWorld today

vaccine efficacy

Deliberately infecting healthy volunteers with malaria parasites: Perceptions and experiences of participants and other stakeholders in a Kenyan-based malaria infection study

July 13, 2020 - 16:19 -- Open Access
Author(s): 
Jao I, Marsh V, Che Chi P, Kapulu M, Hamaluba M, Molyneux S, Bejon P, Kamuya D
Reference: 
Bioethics. 2020 Jul 9

Controlled human malaria infection (CHMI) studies involve the deliberate infection of healthy volunteers with malaria parasites under controlled conditions to study immune responses and/or test drug or vaccine efficacy. An empirical ethics study was embedded in a CHMI study at a Kenyan research programme to explore stakeholders’ perceptions and experiences of deliberate infection and moral implications of these.

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi

June 15, 2020 - 15:39 -- Open Access
Author(s): 
Bell GJ, Loop MS, Hoffman I, et al.
Reference: 
BMC Public Health. 2020 Jun 12; 20(1):910

RTS,S/AS01 is the first vaccine against malaria to undergo pilot implementation, beginning in 2019 and vaccinating 360,000 children per year in Malawi, Ghana, and Kenya. The four-dose vaccine is given as a primary three-dose series with a fourth dose given approximately 18 months later. The efficacy of RTS,S/AS01 was variable among the 11 sites participating in the 2009–2014 phase III trial (MALARIA-055, NCT00866619), possibly due to differences in transmission intensity. However, a within-site examination of environmental factors related to transmission intensity and their impact on vaccine efficacy has yet to be conducted.

Subscribe to RSS - vaccine efficacy